TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04777383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Iontophoretic administration of 5 different concentrations of norepinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Iontophoretic administration of 5 different concentrations of phenylephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Iontophoretic administration of 5 different concentrations of atropine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: Iontophoretic administration of 5 different concentrations of neostigmine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile water
Description: Iontophoretic administration of sterile water
Study: NCT04046445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSV-GP128
Description: 1 single IV injection
Study: NCT04029090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.
Study: NCT04029090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single dose of 0.9% w/v saline over 60 min will be intravenously administered.
Study: NCT03658343

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: T2* Imaging
Description: T2\* imaging sequences for MRI
Study: NCT01953198

Intervention type: OTHER
Intervention: Hypobaric hypoxia
Description: Subjects are exposed to hypobaric hypoxia in the context of a high altitude expedition.
Study: NCT03048565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Mindfulness is a skill that helps people manage their thoughts so that the stressful impact of unhelpful thoughts can be limited. The aim of the mindfulness based intervention in this study is to help caregivers manage stressful thoughts and events and help them respond to life stressors in a positive way.
Study: NCT01661777

Intervention type: DRUG
Group type: OTHER
Intervention: Nasal steroid
Study: NCT01871571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01661777

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myringotomy tube placement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretic
Study: NCT00000105

Intervention type: BIOLOGICAL
Intervention: Intracel KLH Vaccine
Description: Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly.

Intervention type: BIOLOGICAL
Intervention: Biosyn KLH
Description: Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly.
Study: NCT01661777

Intervention type: DRUG
Group type: OTHER
Intervention: Antihistamine

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low salt diet
Study: NCT01605604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: buddhist mind fullness
Description: there are two group one group recieve Buddhist mindfulness group intervention 8 times second group recieve nothing
Study: NCT02342457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Child suspected of Hirschsprung disease
Description: Children admitted for rectal biopsy, due to chronic constipation and suspected of Hirschsprungs disease, will undergo electrophysiological reading from the rectal inner wall, at thechosen site for biopsy before biopsy is performed. Histopathology and readings will be analyzed for corelation
Study: NCT03070223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: One tablet (4 mg) taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
Study: NCT00000105

Intervention type: BIOLOGICAL
Intervention: Biosyn KLH
Description: Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly.
Study: NCT03070223

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: One tablet taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
Study: NCT03926572

Intervention type: OTHER
Group type: OTHER
Intervention: A biobank will be created from blood samples taken at admission, days 3 and days 7
Description: A biobank will be created from the blood samples taken on admission, days 3 and 7 of admission. The prognostic value of the preselected biomarkers will be analyzed and a proteomic analysis will be performed to identify new biomarkers. The prognostic value of these new biological parameters will be compared to the usual surveillance parameters that will be collected during the follow-up (clinical, echocardiographic and hemodynamic parameters)
Study: NCT03635424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic TAVR Systems
Description: Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
Study: NCT00767663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dipyridamole
Description: dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo twice daily, minimal three days pretreatment
Study: NCT01424748

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tahitian Noni Juice
Description: noni fruit juice
Study: NCT00000105

Intervention type: DRUG
Intervention: Montanide ISA51
Description: Emulsify the KLH with Montanide ISA-51. The KLH 1 mg vial will be reconstituted in 0.5 mL sterile water. Once solubilized, add 0.6 mL of Montanide ISA to the vial and administered contents subcutaneously.

Intervention type: BIOLOGICAL
Intervention: Tetanus toxoid
Description: Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.
Study: NCT01424748

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tahitian Noni Juice
Description: noni fruit juice

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tahitian Noni Juice
Description: noni fruit juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo juice
Study: NCT01753869

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Airways clearance and Hypertonic saline inhalation
Study: NCT04691960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis. The diet will begin at an approximately 3:1 fat to carbohydrate + protein ratio for 5 days. If the patient does not show urine ketosis (1.5 mmol/L or 27.0 mg/dL), the ketosis diet will be advanced to approximately 4:1 ratio for 5 days. If the patient still does not attain ketosis a 24 hour fast will be done to promote ketosis. The diet will encourage at least 30 ml per day of Medium Chain Triglycerides (MCT) oil to enhance ketosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be administered as a single 850 mg dose P.O. at Week 8, then titrated up to 850 mg P.O. BID at Week 10, and then 850 mg T.I.D. at Week 12, as tolerated.
Study: NCT00000105

Intervention type: BIOLOGICAL
Intervention: Tetanus toxoid
Description: Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.

Intervention type: BIOLOGICAL
Intervention: Tetanus toxoid
Description: Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.
Study: NCT05348070

Intervention type: PROCEDURE
Intervention: Laparoscopy/Laparotomy
Description: All patients included in the study were operated patients.

Intervention type: PROCEDURE
Intervention: Laparoscopy/Laparotomy
Description: All patients included in the study were operated patients.
Study: NCT03011814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT01781468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil 150 mg
Description: given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil 250 mg
Description: given orally
Study: NCT02324569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets
Study: NCT00791245

Intervention type: BIOLOGICAL
Intervention: Particulated Juvenile Cartilage Allograft
Description: Particulated Juvenile Cartilage Allograft
Study: NCT02395380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C-reactive protein dosage
Study: NCT04669782

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K (MK7)
Description: MK-7 will be administered at a dose of 375 microg / day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Teriparatide will be administered as standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Teriparatide will be administered as standard of care
Study: NCT02852824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655130 (spesolimab)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00999336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: 80 mg betrixaban qd for 8 days
Study: NCT03541980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline volume equivalent
Study: NCT03745157

Intervention type: DRUG
Intervention: Insulin Degludec/Insulin Aspart
Description: Patients will be treated with commercially available Insulin Degludec/Insulin Aspart (Ryzodeg®) in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the treating physician in accordance with the Ryzodeg® label in Japan
Study: NCT00999336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: 80 mg betrixaban qd for 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: 80 mg betrixaban qd for 8 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betrixaban
Description: 80 mg betrixaban qd for 8 days
Study: NCT06778200

Intervention type: OTHER
Intervention: client interview
Description: using a data collection form clients voluntarily described services provided by practitioner

Intervention type: OTHER
Intervention: practitioner responses
Description: completed reflections after each module completion
Study: NCT01352221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST10
Description: 30 mg capsules to be taken orally twice a day for 12 weeks in double-blind phase
Study: NCT03791736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of sandostatine
Description: Intramuscular injection of sandostatin 30 mg 3 days before surgery
Study: NCT01012063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron sucrose, erythropoietin-β
Description: The 200 mg of iron sucrose diluted with 100 ml of normal saline was given intravenously over one hour and the 3000 IU of Epo-β was injected subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 100 ml of normal saline was given intravenously over one hour and 0.5ml was injected subcutaneously.
Study: NCT02337829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib (Arm A)
Description: * A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;~* A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.~* A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;~* A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib (Arm A)
Description: * A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;~* A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.~* A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;~* A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib (Arm B)
Description: B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;~• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib (Arm B)
Description: B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;~• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y.
Study: NCT04064060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution
Study: NCT02143726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: Given PO
Study: NCT06778161

Intervention type: PROCEDURE
Group type: OTHER
Intervention: nerve block
Description: Nerve block for providing analgesia after thoracotomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: nerve block
Description: Nerve block for providing analgesia after thoracotomy
Study: NCT01352221

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase
Study: NCT03219034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral appliance - A ; washout; oral appliance B
Description: Anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible. 1 week washout followed by anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral appliance - A ; washout; oral appliance B
Description: Anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible. 1 week washout followed by anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral appliance - B; washout; oral appliance A
Description: Anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs. 1-week washout followed by anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral appliance - B; washout; oral appliance A
Description: Anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs. 1-week washout followed by anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.
Study: NCT02143726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO
Study: NCT03092674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03774082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC424
Description: Ruxolitinib is taken orally either as 5mg tablets or as pediatric formulation (dosage based on age group)
Study: NCT00855036

Intervention type: OTHER
Intervention: Attenuated bedrest
Description: Patients are allowed to ambulate the morning after admission and then can be discharged when eating well and pain is controlled on oral pain medication regardless of hematuria
Study: NCT03707899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1401
Description: Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
Study: NCT01691105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AD + Integrated Tobacco Order Set
Description: Physician will have access to:~NRT with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center
Study: NCT01597908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib 150 mg twice daily orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemurafenib
Description: Vemurafenib 960 mg twice daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2 mg once daily orally
Study: NCT03007329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide will be combined with Dapagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide matching Placebo
Description: Exenatide matching Placebo will be combined with Dapagliflozin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin, in both arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin, in both arms
Study: NCT02674919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic Hamstring

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Study: NCT01186926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HGNS Treatment
Description: The Apnex Hypoglossal Nerve Stimulation (HGNS) System is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping, and off when the patient is awake.
Study: NCT01287390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video fluoroscopy
Description: video fluoroscopy of swallowing function at baseline, 6 months and 12 months follow-up
Study: NCT03707899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JLP-1401
Description: Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine, Rosuvastatin
Description: Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine, Rosuvastatin
Description: Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)